Memantine is a prescription drug used to treat moderate to severe Alzheimer's disease. It is an NMDA receptor antagonist primarily used to manage neuropsychiatric symptoms in dementia patients. Memantine provides cognitive benefits for patients suffering from Alzheimer's and other dementias. It improves memory, thinking, language skills, understanding, and judgement in patients experiencing moderate to severe cognitive decline due to Alzheimer's disease.
The global Memantine Market is estimated to be valued at Us$ 921.6 Mn in 2024 and is expected to exhibit a CAGR Of 5.2% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
One of the major opportunities in the memantine market is improved cognitive functionality in dementia patients. According to WHO, around 55 million people globally are living with dementia, with numbers expected to rise to 78 million by 2030 and 139 million by 2050. Memantine helps dementia patients by binding to and obstructing NMDA receptors in the brain and reducing glutamate levels. This has been seen to improve cognitive abilities like memory, thinking, planning, judgement and language skills in patients suffering from moderate to severe dementia. The drug provides benefits for 3-6 months in cognition, behavior and ability to perform daily tasks. This establishes memantine as an important treatment option for millions suffering from Alzheimer's disease worldwide and represents a major market opportunity over the forecast period.
Porter's Analysis
Threat of new entrants: The threat of new entrants is moderate as memantine market requires extensive R&D and clinical trials for products. However, specialty pharma companies can enter the market.
Bargaining power of buyers: The bargaining power of buyers is moderate as memantine is supplied by a handful of suppliers and buyers have limited options.
Bargaining power of suppliers: The bargaining power of suppliers is high as memantine production is specialized and suppliers have a cost advantage.
Threat of new substitutes: The threat of new substitutes is low as memantine is clinically proven and very few alternatives exist for its application in Alzheimer's disease.
Competitive rivalry: The competitive rivalry is high as key players compete on branding, promotion activities, and patents.
SWOT Analysis
Strength: Memantine is clinically proven for moderate to severe Alzheimer's with good safety profile. It provides an alternative treatment option.
Weakness: Memantine has limited efficacy compared to other late-stage treatments and requires regular medical supervision. Its patent protection is also eroding.
Opportunity: Demographic trends indicate growing Alzheimer's population. Emerging markets offer future revenue potential.
Threats: Price controls and regulatory approvals can impact revenues. Generics pose pricing and competitive challenges after patent expiry.
Key Takeaways
The Global Memantine Market Demand is expected to witness high growth supported by rising Alzheimer's disease prevalence. The market size for 2024 is estimated at US$ 921.6 million and is forecast to reach US$ 1,504.5 million by 2031 growing at a CAGR of 5.2% during the forecast period from 2024 to 2031.
Regional analysis:
North America currently dominates the memantine market and is expected to maintain its lead through 2031. This is attributed to growing Alzheimer's population, lucrative reimbursements, and high treatment rates in the region. Europe follows North America in terms of market value and volume share due to supportive public healthcare. Asia Pacific is emerging as the fastest growing regional market for memantine driven by unmet needs, improving healthcare infrastructure, and rising middle-class population in major Asian countries.
Key players operating in the memantine market are Merz Pharma, Allergan, Lundbeck, Novartis, Johnson & Johnson, Eisai, and Teva Pharmaceuticals. Merz Pharma has strong presence for Namenda brand with expiring patents. Allergan markets Namzaric and has emerging generic pipeline. Lundbeck is known for Axura and Ebixa brands and has leadership in European region.
Get more insights on this topic :
Check more trending articles on this topic:
Latest Research Report on “Sports Medicine Products Market” Added by Analytical Research Cognizance which covers Market Overview, Future Economic Impact, Competition by Manufacturers, Supply (Production), & Consumption Analysis
This report studies the global market size of Sports Medicine Products Market in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Sports Medicine Products in these regions.
This report also studies the global Sports Medicine Products market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
Get Sample for Sports Medicine Products Market Report @ http://www.arcognizance.com/enquiry-sample/131077
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Market size by End User
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.
Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.
Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.
Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
The On-demand Taxi Booking market research primarily focuses on the market size, growth, changing trends, factors that are impacting the present market over the period from 2020-2027.
Read on the blog to know more.
This report studies the global market size of Robotic Surgery Systems in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Robotic Surgery Systems in these regions.
This report also studies the global Robotic Surgery Systems market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
Market size by End User
Rest of Central & South America
The study objectives of this report are:
To study and analyze the global Robotic Surgery Systems market size (value & volume) by company, key regions, products and end user, breakdown data from 2013 to 2017, and forecast to 2025.
